Skip to main content
. Author manuscript; available in PMC: 2024 Apr 13.
Published in final edited form as: Cell. 2023 Apr 13;186(8):1610–1626. doi: 10.1016/j.cell.2023.03.010

Figure 5. EVs as anti-cancer therapeutic agents.

Figure 5.

Distinct cellular sources have been used to generate EVs in large scale for clinical trials. EVs engineering include the incorporation of a cargo (e.g. ASO, siRNA, chemotherapeutics etc), enriching for exosomes with unique surface protein presentation (e.g. antigen, immune modifying receptor). Preclinical studies in various tumor models and tumor types informed ongoing clinical trial design. EVs offer a novel therapeutic platform for cancer treatment, from personalized medicine to immunotherapy and targeted therapy with novel safety and efficacy profiles. Created with BioRender.com.